L A Donnelly
Overview
Explore the profile of L A Donnelly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Best D, Gauger T, Dolan J, Donnelly L, Ranganathan K, Ulloa-Marin C, et al.
Int J Oral Maxillofac Surg
. 2018 Jun;
47(11):1373-1380.
PMID: 29945819
There is a growing demand for surgical care in South America, particularly for patients with congenital orofacial clefts (OFCs). Short-term surgical missions (STSMs) have emerged as a means to deliver...
2.
Noyes J, Soto-Pedre E, Donnelly L, Pearson E
Diabet Med
. 2017 Jul;
35(2):262-269.
PMID: 28755478
Aims: Increased visit-to-visit glycaemic variability is independently associated with adverse outcomes in Type 2 diabetes. Our aim was to identify the patient characteristics associated with raised visit-to-visit glycaemic variability in...
3.
Meng W, Deshmukh H, van Zuydam N, Liu Y, Donnelly L, Zhou K, et al.
Eur J Pain
. 2014 Jul;
19(3):392-9.
PMID: 24974787
Background: Neuropathic pain, caused by a lesion or a disease affecting the somatosensory system, is one of the most common complications in diabetic patients. The purpose of this study is...
4.
Donnelly L, Doney A, Tavendale R, Lang C, Pearson E, Colhoun H, et al.
Clin Pharmacol Ther
. 2010 Dec;
89(2):210-6.
PMID: 21178985
SLCO1B1 gene variants are associated with severe statin-induced myopathy. We examined whether these variants are also associated with general statin intolerance in a large population of patients with type 2...
5.
Donnelly L, Morris A, Pearson E
Diabetes Obes Metab
. 2009 Mar;
11(4):338-42.
PMID: 19267712
Aim: Metformin is the most commonly prescribed oral agent used in the treatment of type 2 diabetes. It is effective at reducing glycosylated Haemoglobin (HbA1c) and decreasing microvascular and macrovascular...
6.
Donnelly L, Doney A, Morris A, Palmer C, Donnan P
Diabet Med
. 2008 Jul;
25(7):850-5.
PMID: 18644071
Aims: To determine the patterns and predictors of long-term adherence to statin therapy in all patients with diabetes in the community setting. Methods: We retrospectively studied patients with diabetes who...
7.
Donnelly L, Morris A, Evans J
QJM
. 2007 May;
100(6):345-50.
PMID: 17504861
Background: Good glycaemic control improves outcomes in patients with type 2 diabetes, but the extent to which this depends on adherence to insulin treatment is uncertain. Aim: To investigate the...
8.
Donnelly L, Doney A, Hattersley A, Morris A, Pearson E
Diabet Med
. 2006 Jan;
23(2):128-33.
PMID: 16433709
Aims: In treating Type 2 diabetes (T2DM), UK guidelines recommend metformin in obese and overweight patients, and either sulphonylureas or metformin in normal weight patients. Although other factors influence prescribing...
9.
Donnelly L, Morris A, Frier B, Ellis J, Donnan P, Durrant R, et al.
Diabet Med
. 2005 May;
22(6):749-55.
PMID: 15910627
Aims: To ascertain the frequency and identify predictors of self-reported hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes. Methods: A random sample of 267 people with insulin-treated diabetes were...